Massachusetts gastrointestinal disease firm, Cristcot, has announced results from its Phase III trial examining its hydrocortisone suppository and applicator for ulcerative colitis (UC), finding ...

Results from the Phase III ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) trials showed that Abivax’s obefazimod demonstrated significant clinical remission in patients with ulcerative colitis.

Investing.com -- Abivax shares rose over 400% in Paris on Wednesday after the French biotech company announced that its lead drug candidate obefazimod achieved primary endpoints in two Phase 3 ...

The latest announcement is out from Abivax SA Sponsored ADR ( (ABVX) ).

NORTH CHICAGO, Ill., June 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from COMMAND, its Phase 3 maintenance study, showing risankizumab (SKYRIZI ®, 180 mg or ...

Summary. clinical trial report, “Ulcerative Colitis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2023 Update" provides ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, ...

After a long, cash-strapped journey, French biotech Abivax has presented top-line data from the twin phase 3 trials of its lead ulcerative colitis candidate.  | After a long, cash-strapped journey, ...

Eli Lilly and Company announced that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week phase 3 induction study evaluating the efficacy and safety of mirikizumab for ...

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease Teva hosting ...

PARIS - Abivax SA (Euronext Paris:FR0012333284 - ABVX / Nasdaq: ABVX), a clinical-stage biotechnology company with a market capitalization of $669 million, announced Tuesday that its oral ulcerative ...

Investing.com -- Abivax shares rose over 400% in Paris on Wednesday after the French biotech company announced that its lead drug candidate obefazimod achieved primary endpoints in two Phase 3 ...